Kezar Life Sciences terminates HQ lease, separates CEO, CFO, and COO ahead of Aurinia merger

Kezar Life Sciences, Inc.

Lease for ~48,714 sq ft at 4000 Shoreline Court terminated April 1; company pays $2M ( $1.3M cash + $0.7M security deposit).
CEO Christopher Kirk, CFO Marc Belsky, and COO Mark Schiller enter separation agreements; employment ends at merger close or earlier.
Kirk receives lump-sum severance of 18 months base salary plus pro-rata bonus; Belsky and Schiller get 12 months COBRA cash payment.
No disagreements between officers and company; severance contingent on signing general release.
Merger with Aurinia Pharma U.S. at $6.955/share plus CVR still expected to close.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Kezar Life Sciences, Inc. terminated Lease Termination Agreement with GNS South Tower, LP valued at $2 million (effective 2026-04-01).

Action: termination
Agreement: lease
Counterparty: GNS South Tower, LP
Value: $2 million
Effective: 2026-04-01

Exact text from the filing

On April 1, 2026, Kezar Life Sciences, Inc. (the “Company”) entered into a lease termination agreement (the “Lease Termination Agreement”) with GNS South Tower, LP (the “Landlord”) to terminate that certain lease agreement, dated as of August 16, 2017, as amended (the “Lease”), for approximately 48,714 rentable square feet at 4000 Shoreline Court, San Francisco, California.

View on SEC.gov

Browse all material agreements →

Kezar Life Sciences, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-26-023703

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.